We share @mndassoc’s disappointment at NICE’s initial guidance on tofersen.
This isn’t the final decision, and specialist treatments often need more than one round of appraisal. We’ll keep supporting the process so people living with SOD1-#mnd can access it.
We are sorry to have to share the news that the National Institute for Health and Care Excellence (NICE) has published initial guidance that the life-saving drug tofersen should not be made routinely available on the NHS.
This isn't the end of the process, but we appreciate this will be difficult news for the MND community to hear. It's unthinkable that the 2% of people with MND could be denied access to an effective treatment that's available in other countries.
We want you to know our work does not stop here. We'll be sharing an e-action in the next few days and working on our response to NICE's initial guidance.
Read our full statement here. 🔗www.mndassociation.org/media/latest-news/nice-initial-rec…










































































































































































































































































































































































































































































































































































































































































